182 related articles for article (PubMed ID: 8341645)
1. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Kalland T; Abramsky O
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6400-4. PubMed ID: 8341645
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
Ann Neurol; 1993 Nov; 34(5):654-60. PubMed ID: 8239559
[TBL] [Abstract][Full Text] [Related]
3. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats.
Zhu J; Diab A; Mustafa M; Levi M; Wahren B; Björk J; Hedlund G
J Neurol Sci; 1998 Oct; 160(2):113-20. PubMed ID: 9849793
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis.
Lehmann D; Karussis DM; Fluresco D; Mizrachi-Koll R; Ovadia H; Shezen E; Kalland T; Abramsky O
J Neuroimmunol; 1997 Apr; 74(1-2):102-10. PubMed ID: 9119961
[TBL] [Abstract][Full Text] [Related]
5. Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis.
Drescher KM; Rivera-Quinones C; Lucchinetti CF; Rodriguez M
J Neuroimmunol; 1998 Aug; 88(1-2):111-9. PubMed ID: 9688332
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation of experimental autoimmune myasthenia gravis with linomide.
Karussis DM; Lehmann D; Brenner T; Wirguin I; Mizrachi-Koll R; Sicsic C; Abramsky O
J Neuroimmunol; 1994 Dec; 55(2):187-93. PubMed ID: 7829669
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages.
Dahlén E; Andersson M; Dawe K; Tellander AC; Brunmark C; Björk A; Hedlund G
Autoimmunity; 2000 Oct; 32(3):199-211. PubMed ID: 11092700
[TBL] [Abstract][Full Text] [Related]
8. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines.
Diab A; Michael L; Wahren B; Deng GM; Björk J; Hedlund G; Zhu J
J Neuroimmunol; 1998 May; 85(2):146-54. PubMed ID: 9630163
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation of autoimmunity by linomide.
Karussis DM; Lehmann D; Slavin S; Kalland T; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Abramsky O
Isr J Med Sci; 1995 Jan; 31(1):38-41. PubMed ID: 7836046
[No Abstract] [Full Text] [Related]
10. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Neurology; 1996 Oct; 47(4):895-900. PubMed ID: 8857715
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation with linomide: possible novel therapy for multiple sclerosis.
Abramsky O; Lehmann D; Karussis D
Mult Scler; 1996 Nov; 2(4):206-10. PubMed ID: 9345375
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids.
Pekarski O; Björk J; Hedlund G; Andersson G
Autoimmunity; 1998; 28(4):235-41. PubMed ID: 9892505
[TBL] [Abstract][Full Text] [Related]
13. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis DM; Meiner Z; Lehmann D; Gomori JM; Schwarz A; Linde A; Abramsky O
Neurology; 1996 Aug; 47(2):341-6. PubMed ID: 8757002
[TBL] [Abstract][Full Text] [Related]
14. Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes.
Karussis D; Abramsky O; Rosenthal Y; Mizrachi-Koll R; Ovadia H
Immunol Lett; 1999 Apr; 67(3):203-8. PubMed ID: 10369127
[TBL] [Abstract][Full Text] [Related]
15. Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice.
Erälinna JP; Röyttä M; Hukkanen V; Zinhu D; Salmi AA; Salonen R
J Neuroimmunol; 1998 Aug; 88(1-2):165-76. PubMed ID: 9688338
[TBL] [Abstract][Full Text] [Related]
16. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
17. The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice.
Morecki S; Nabet C; Falk P; Fridkis-Hareli M; Pecht I; Mond JJ; Slavin S
Autoimmunity; 1997; 25(4):223-32. PubMed ID: 9344330
[TBL] [Abstract][Full Text] [Related]
18. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.
Gross DJ; Weiss L; Reibstein I; Hedlund G; Dahlén E; Rapoport MJ; Slavin S
Int Immunopharmacol; 2001 Jun; 1(6):1131-9. PubMed ID: 11407307
[TBL] [Abstract][Full Text] [Related]
19. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses.
Zhu J; Bai XF; Hedlund G; Björk J; Bakhiet M; Van Der Meide PH; Link H
Clin Exp Immunol; 1999 Jan; 115(1):56-63. PubMed ID: 9933420
[TBL] [Abstract][Full Text] [Related]
20. The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.
Condiotti R; Slavin S; Barak V; Nagler A
Leuk Res; 1996 Jan; 20(1):57-63. PubMed ID: 8632678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
